CGTLive®’s Weekly Rewind – March 14, 2025

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Stem Cell Therapy CALEC Restores Corneal Damage in Trial Led by Massachusetts Eye and Ear Investigators

CALEC completely restored the cornea in 50% of participants at their 3-month visit and that rate of complete success increased to 79% and 77% at their 12- and 18-month visits, respectively.

2. John Brandsema, MD, on the Roadblocks Faced by Gene Therapies for Muscular Dystrophies

The pediatric neurologist at Children’s Hospital of Philadelphia offered insights into the obstacles the clinical community is facing around integrating gene therapies into clinical practice.

3. Longeveron's Cell Therapy Lomecel-B Improves Cognitive Function in Mild Alzheimer Disease

The study included 48 patients, 36 of whom received laromestrocel and 12 of whom received a placebo.

4. ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhD

In Episode 2 of ImmunoLogic, Bruce Levine, PhD, discussed the current the risk-benefit-ratio for CAR-T therapy.

5. ASGCT’s Q4 2024 Landscape Report Indicates Steady Rate of Growth

David Barrett, JD, the chief executive officer of ASGCT, broke down the highlights of the organization’s final report for 2024